Back To Search Instructions
Protocols
13 protocols meet the specified criteria
Disease Site: Melanoma, skin
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
1200000229Skin Cancer Prevention Program BiorepositoryOpen
1409505107Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated LightOpen
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1701158847A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma To evaluate the efficacy with respect to progression-free survival (PFS) of MK-3475 administered intravenously in combination with oral dabrafenib and trametinib in subjects with advanced (unresectable or metastatic) melanoma with BRAF V600 E or K mutations, compared with placebo administered intravenously in combination with oral dabrafenib and trametinib alone. Open
1703270664A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic MelanomaOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1705427831A prospective, randomized, blinded, placebocontrolled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrenceOpen
1706546860A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic DiseaseOpen
1709869722A PHASE III, OPEN-LABEL, MULTICENTER,TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMAOpen
1711993805An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in PatientsOpen
1803383790A Phase 1 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) From BRAF or MEK-Mutated Metastatic MelanomaOpen
PHXE-17-0216-10-15EAY131: Molecular Analysis for Therapy Choice (MATCH) Open